Shots:
- Rani Therapeutics has entered into a research and development collaboration with PegBio to evaluate delivery of multiple obesity & metabolic disease candidates using its proprietary RaniPill platform
- As per the deal, Rani and PegBio will collaborate on the preclinical development of RaniPill formulations for selected obesity & metabolic disease candidates, aiming to advance the most promising into clinical development
- The collaboration builds upon Rani’s obesity franchise, incl. Phase 1 RT-114 (partnered with ProGen) & preclinical oral semaglutide & other candidates that demonstrated PK, bioavailability, PD, and weight loss comparable to SC injections
Ref: Globenewswire | Image: Rani Therapeutics & PegBio | Press Release
Related News: Biocytogen Collaborates with Whitehawk Therapeutics to Develop Bispecific ADC
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with usatconnect@pharmashots.com
